PLAINSBORO, N.J., March 21, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corp. (Nasdaq:IART) today announced the successful implantation of over 4,000 Integra® IPP-ON® PIP Fusion Systems. The system is a valuable addition to Integra's broad range of products for orthopedic surgeons and podiatrists, which spans the continuum of care from internal fixation to joint replacement to wound care solutions.
The IPP-ON PIP Fusion System is designed for fixation of proximal interphalangeal (PIP) joint arthrodesis of the lesser toes, and offers surgeons a straightforward alternative to k-wire fixation. It is a one-piece, stainless steel interphalangeal fusion device that offers both cortical and cancellous fixation, and is available in two sizes to accommodate varying patient anatomy.
"This is a great milestone for our company, and an excellent example of Integra's commitment to design products that help limit uncertainty for surgeons," said Bill Weber, Integra's Vice President and General Manager, Extremity Reconstruction. "The IPP-ON PIP Fusion System requires no special handling and can be stored at room temperature, allowing surgeons to use it whenever and wherever they need it."
Integra's IPP-ON PIP Fusion System will be available at Integra's booth (3465) at the 2013 AAOS Annual Meeting in Chicago, Illinois, March 20-22, 2013. Integra will also offer live demonstrations and opportunities for hands-on experience of its products.
Integra hosts surgical workshops throughout the United States, which feature its foot and ankle, shoulder, wrist, hand, elbow, spine and regenerative product lines. Visit http://www.integralife.com to find a workshop near you.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com.
The Integra LifeSciences Holdings Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=440
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella Director, Corporate Communications (609) 936-2389 email@example.com
Source:Integra LifeSciences Holdings Corp.